Press Releases

Investor Alerts

Sep 3, 2019

Satsuma Pharmaceuticals Announces Poster Presentations at the International Headache Congress
Sep 3, 2019

Satsuma Pharmaceuticals, Inc. Announces Proposed Initial Public Offering of Common Stock
Aug 22, 2019

Satsuma Pharmaceuticals Announces First Patient Dosed in EMERGE™, a Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine
Jul 8, 2019

Satsuma Pharmaceuticals Announces Presentation of STS101 (Dihydroergotamine Nasal Powder) Phase 1 Trial Results at American Headache Society's Annual Scientific Meeting

-- Favorable Pharmacokinetic, Safety, and Tolerability Results Support Advancing STS101 into Pivotal Phase 3 Efficacy Trial
May 29, 2019

Satsuma Pharmaceuticals Appoints Elisabeth Sandoval to Board of Directors

-- Commercial leader brings recent migraine space experience to Satsuma as it advances lead product candidate STS101 into Phase 3 development --

Show per page